Articles by tag: oncology

Lung cancer drug Lurbinectedin approved in Europe

Europe approved the world's first Lurbinectedin drug with immunotherapy for aggressive lung cancer. 46% reduction in risk of death. Learn about the breakthrough and forecasts.

EMA approval of first-line treatment for aggressive colon cancer

EMA recommended encorafenib + cetuximab + FOLFOX for first-line BRAF V600E-mutant mCRC. 47% reduction in risk of progression. Read analysis and BREAKWATER study data.

Targeted therapy for ultra-rare blood cancer: FDA approves pivekimab sunirin

FDA has registered the first targeted therapy for BPDCN — pivekimab sunirin. Remission rate 69.7%, but there are risks. Detailed analysis of the drug and consequences.

AI triples sensitivity of early pancreatic cancer detection

Mayo Clinic's REDMOD model detects pancreatic cancer 475 days before diagnosis with 73% sensitivity. Learn how AI is changing oncology and who needs screening now.

CRISPR stem cells against blood cancer: breakthrough or failure

Analysis of a clinical trial: how edited stem cells are changing therapy for acute myeloid leukemia. Learn about hidden risks and the economics of the method.

Nanotechnology against cancer chemoresistance: a review from EUR J CANCER

Breakthrough in oncology: how nanoparticles and CRISPR epigenome editing reverse tumor resistance to chemotherapy. Learn about clinical successes in 2026.